Adams et al. engineered a tumor vaccine by isolating ascites-derived monocytes from ID8 tumor-bearing mice and stimulating with Toll-like receptor (TLR) 4 lipopolysaccharide, TLR 9 CpG-oligonucleotides, and IL-10R antibody. This evidence concerns the gene IL10RA and neoplasm.